The mission of any Biotech company management is to bring drug(s) to market. That is, develop, test, take them through the regulatory process and, eventually, commercialize them to help patients.
In light of the 13D and the future of CYDY, this is what we should judge, and base decisions on, in regards to our current/future leadership.
Our current management hasn’t been able to finalize a FDA (or otherwise) approval yet. Why ??
It is very difficult,
I believe we have a lopsided FDA board tainted by BP
We have made mistakes
We don’t have a large economical muscle.
It is evident is that Leronlimab works. The 13D group is not fighting to gain control of a failing drug. By the contrary, they know ,and “we” know, we are in the presence of a wonder drug.
Do we need to replace our current management ??. I leave to anyone to make its own decisions.
I personally think that current management took Leronlimab to the trial in COVID Severe-critical rapidly and accomplished it successfully (as far as execution goes). The trial did not meet main end point(s) due to a design flaw: when we changed from 2 to 4 weeks the primary-point measures we should have correspondingly changed the dosage from 2 to 4. Or stick to 2 weeks duration. This was a mistake. Not sure if it was forced or unforced, but this is the reason the SP is not north of $10 right now.
Of course, this is Monday mornig coaching. The trial for HIV has been delayed, this in part for an unfortunate sequence of events: COVID and the occupancy measurements were both, management and FDA are responsible. But we are almost there.
Is there anything that management could have done better ??? Of course, but, again, is too easy to judge in retrospective. There are things that I like and dislike about our current management (could make a long list of both), however, in general, I am content with the way things are going with the trials .
As a consequence, I am in favor of keeping the current management in place as they are moving at a fast pace in many fronts (in spite of the economical limitations), have the experience of past mistakes and have the energy and vision to take us to the goal.
Also, we should remember that we were not initially a COVID company, it so happens that Leronlimab works for COVID. We should be jumping up and down of joy in that this was an unexpected "gift"
, sometimes I wished we were more focused in our HIV and Oncology platforms. These will be huge when all is said and done
I do respect opinions to the contrary, but whatever the case might be, we are in the presence of a great drug that is needed out there.
In light of the 13D and the future of CYDY, this is what we should judge, and base decisions on, in regards to our current/future leadership.
Our current management hasn’t been able to finalize a FDA (or otherwise) approval yet. Why ??
It is very difficult,
I believe we have a lopsided FDA board tainted by BP
We have made mistakes
We don’t have a large economical muscle.
It is evident is that Leronlimab works. The 13D group is not fighting to gain control of a failing drug. By the contrary, they know ,and “we” know, we are in the presence of a wonder drug.
Do we need to replace our current management ??. I leave to anyone to make its own decisions.
I personally think that current management took Leronlimab to the trial in COVID Severe-critical rapidly and accomplished it successfully (as far as execution goes). The trial did not meet main end point(s) due to a design flaw: when we changed from 2 to 4 weeks the primary-point measures we should have correspondingly changed the dosage from 2 to 4. Or stick to 2 weeks duration. This was a mistake. Not sure if it was forced or unforced, but this is the reason the SP is not north of $10 right now.
Of course, this is Monday mornig coaching. The trial for HIV has been delayed, this in part for an unfortunate sequence of events: COVID and the occupancy measurements were both, management and FDA are responsible. But we are almost there.
Is there anything that management could have done better ??? Of course, but, again, is too easy to judge in retrospective. There are things that I like and dislike about our current management (could make a long list of both), however, in general, I am content with the way things are going with the trials .
As a consequence, I am in favor of keeping the current management in place as they are moving at a fast pace in many fronts (in spite of the economical limitations), have the experience of past mistakes and have the energy and vision to take us to the goal.
Also, we should remember that we were not initially a COVID company, it so happens that Leronlimab works for COVID. We should be jumping up and down of joy in that this was an unexpected "gift"
, sometimes I wished we were more focused in our HIV and Oncology platforms. These will be huge when all is said and done I do respect opinions to the contrary, but whatever the case might be, we are in the presence of a great drug that is needed out there.
54
1
